Mumbai, India | 27 July 2026: Galderma, a global dermatology-focused company, has announced the launch of Sculptra® in India, introducing what the company describes as the first clinically proven regenerative biostimulator in the country’s injectable aesthetics market. Supported by more than 25 years of global clinical evidence, Sculptra® is designed to stimulate the body’s natural collagen production, helping restore facial volume and improve skin quality through a gradual, regenerative approach when administered by qualified healthcare professionals.
The introduction of Sculptra® comes as India’s aesthetic medicine sector continues to evolve, driven by growing awareness of skin health, increasing demand for minimally invasive procedures, and a preference for personalized treatment approaches. Healthcare professionals and patients are increasingly exploring regenerative therapies that focus on supporting the skin’s natural biological processes rather than providing temporary aesthetic correction alone.
Introducing a Regenerative Approach to Injectable Aesthetics
Unlike conventional injectable treatments that primarily address visible signs of ageing through immediate correction, Sculptra® is designed to work by stimulating the body’s own collagen production. Through its proprietary PLLA-SCA™ (poly-L-lactic acid) formulation, the treatment gradually supports the restoration of the skin’s underlying structure, helping improve facial volume, skin firmness, and overall skin quality over time.
As collagen production naturally declines with age, structural support within the skin decreases, contributing to volume loss, reduced elasticity, and the appearance of wrinkles. Regenerative bio stimulation seeks to address these underlying changes by encouraging the body’s natural collagen synthesis, resulting in progressive, natural-looking improvements.
Supporting the Evolution of Aesthetic Medicine in India
Commenting on the launch, Raghavendra Sadashiva, Managing Director, Galderma India & South Asia, said:
“At Galderma, we remain committed to advancing dermatological science by introducing innovations that address the evolving needs of both healthcare professionals and patients. The launch of Sculptra® represents an important milestone as regenerative aesthetics continues to gain global recognition. By working with the body’s natural collagen production, the treatment offers healthcare professionals an additional option for patients seeking gradual, natural-looking improvements in facial structure and skin quality.”
Growing Focus on Collagen Regeneration
Globally, aesthetic medicine is increasingly moving towards regenerative treatment strategies that focus on preserving natural facial characteristics while enhancing skin quality over time. Rather than seeking dramatic or immediate changes, many patients are now opting for treatments that support the skin’s own regenerative processes and deliver subtle, long-lasting outcomes.
According to Galderma, Sculptra® has been used by healthcare professionals in more than 40 countries and regions, supported by extensive clinical research and real-world experience spanning over two decades. The company states that the treatment can provide gradual improvements in facial volume and skin quality, with results that may last for more than two years, depending on individual patient characteristics and treatment protocols.
Expanding Galderma’s Injectable Aesthetics Portfolio
Ravi Mittal, Business Unit Head – Aesthetics, Galderma India, said:
“The aesthetics landscape in India is evolving rapidly, with increasing interest in treatments that support long-term skin quality while maintaining natural-looking results. We are seeing greater emphasis on collagen regeneration and therapies that address the underlying biological changes associated with ageing. The introduction of Sculptra® expands the range of science-based treatment options available to healthcare professionals practising regenerative aesthetics.”
The launch further strengthens Galderma India’s injectable aesthetics portfolio and reflects the company’s continued focus on bringing globally established dermatology innovations to the Indian market. Galderma’s portfolio spans injectable aesthetics, dermatological skincare, and therapeutic dermatology, supporting healthcare professionals with evidence-based treatment solutions across a broad spectrum of skin health needs.
About Sculptra®
Sculptra® is a regenerative biostimulator developed using a proprietary PLLA-SCA™ (poly-L-lactic acid) formulation. The injectable treatment is designed to stimulate the body’s natural collagen production, gradually restoring facial volume while improving skin quality and structural support. Supported by more than 25 years of global clinical evidence, Sculptra® is intended to be administered only by qualified and appropriately trained healthcare professionals. Individual suitability and treatment outcomes may vary.
About Galderma
Galderma (SIX: GALD) is a global dermatology-focused company operating in approximately 90 countries. Since its establishment in 1981, the company has developed a science-based portfolio across Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Galderma works in partnership with healthcare professionals to advance dermatological care through research-driven innovations designed to address a wide range of skin health needs worldwide.
